Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SNRS- Sunrise Technologies -- Ignore unavailable to you. Want to Upgrade?

To: majormember who wrote (1654)	9/28/1998 12:19:00 PM
From: Sylvester	Read Replies (2) \| Respond to of 4140

Skane, Following the spike to $10 based on S&P "Stock of the Week, SNRS has performed only a little worse than most small cap stocks, but very much in line with the excellent TA on this thread. Very smart investors who don't necessarily trade took a big, big hit of between 35% and 50% of their portfolio value. Whatever "risk" portion they assign to SNRS ownership leaves them with two choices. Hold or buy back later while making money elsewhere. I'm holding but this is not necessarily wise. TA suggests stagnation but with biomeds, all anyone needs is a positive article appearing virtually anywhere and a big firm recommending a buy with a target price. Typically, you can expect the target to be about double whatever the price is on the day the recommendation is made, with the target date just before the expected FDA approval rate. Historically, you'll see this type of activity 8 to 12 months before the anticipated announcement. You could be totally unaware of news and just follow TA as this all takes place. (Perhaps this is a wiser course) SNRS will move up quickly like it did before but back off as it approached $10. How much will it back off? Ask Rainer. Even without any profit, small cap fund managers now have something to invest in that's almost a sure thing. They'll bring down the price as far as possible and then slowly begin accumulating the stock. When it passes $10, there will be a surge leading up to FDA announcement. Now only two things can happen. FDA approval or FDA conditions for approval. Doesn't matter initially. SNRS will hit it's target (say $14) prior to FDA and a lot of selling (and new buying) will take place. Whether or not we all get rich depends on two things. What happens to the stock around FDA approval, and any competing technology that quickly comes along. $25-30 a share is years off, but we will see $10 to $14 in less than 18 months and that's why I hold without worrying too much. Regards to all, Sylvester